EVOLUS, INC. Retained Earnings
EVOLUS, INC. (EOLS) had Retained Earnings of -$679.77 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-05
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$679.77M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$671.71M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$661.04M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$661.17M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$679.77M 10-Q · filed 2026-08-05 |
| 2026-03-31 | -$671.71M 10-Q · filed 2026-05-04 |
| 2025-12-31 | -$661.04M 10-Q · filed 2026-08-05 |
| 2025-09-30 | -$661.17M 10-Q · filed 2025-11-05 |
| 2025-06-30 | -$645.43M 10-Q · filed 2025-08-05 |
| 2025-03-31 | -$628.29M 10-Q · filed 2025-05-07 |
| 2024-12-31 | -$609.40M 10-K · filed 2026-03-03 |
| 2024-09-30 | -$602.61M 10-Q · filed 2024-11-06 |
| 2024-06-30 | -$583.44M 10-Q · filed 2024-07-31 |
| 2024-03-31 | -$572.09M 10-Q · filed 2024-05-07 |
| 2023-12-31 | -$558.98M 10-K · filed 2025-03-04 |
| 2023-09-30 | -$547.15M 10-Q · filed 2023-11-07 |
| 2023-06-30 | -$530.23M 10-Q · filed 2023-08-02 |
| 2023-03-31 | -$512.09M 10-Q · filed 2023-05-09 |
| 2022-12-31 | -$497.29M 10-K · filed 2024-03-07 |
| 2022-09-30 | -$484.13M 10-Q · filed 2022-11-08 |
| 2022-06-30 | -$463.85M 10-Q · filed 2022-08-02 |
| 2022-03-31 | -$440.38M 10-Q · filed 2022-05-10 |
| 2021-12-31 | -$422.88M 10-K · filed 2023-03-08 |
| 2021-09-30 | -$404.70M 10-Q · filed 2021-11-02 |
| 2021-06-30 | -$385.27M 10-Q · filed 2021-08-04 |
| 2021-03-31 | -$369.67M 10-Q · filed 2021-05-12 |
| 2020-12-31 | -$376.07M 10-K · filed 2022-03-03 |
| 2020-09-30 | -$265.38M 10-Q · filed 2020-10-29 |
| 2020-06-30 | -$253.92M 10-Q · filed 2020-08-10 |
| 2020-03-31 | -$232.79M 10-Q · filed 2020-05-11 |
| 2019-12-31 | -$213.06M 10-K · filed 2021-03-25 |
| 2019-09-30 | -$198.55M 10-Q · filed 2019-11-04 |
| 2019-06-30 | -$171.57M 10-Q · filed 2019-08-12 |
| 2019-03-31 | -$134.00M 10-Q · filed 2019-05-01 |
| 2018-12-31 | -$123.03M 10-K · filed 2020-02-25 |
| 2018-09-30 | -$110.58M 10-Q · filed 2018-11-05 |
| 2018-06-30 | -$98.75M 10-Q · filed 2018-08-02 |
| 2018-03-31 | -$82.32M 10-Q · filed 2018-05-10 |
| 2017-12-31 | -$75.54M 10-K · filed 2019-03-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |